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AHR

:   adjusted hazard ratio

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

BMI

:   body mass index

CI

:   confidence interval

DAA

:   direct‐acting antiviral

HBV

:   hepatitis B virus

HCV

:   hepatitis C virus

HIV

:   human immunodeficiency virus

ICD

:   International Classification of Diseases

IFN

:   interferon

INR

:   international normalized ratio

MGUS

:   monoclonal gammopathy of unknown significance

NS

:   nonstructural protein

SVR

:   sustained virologic response

VA

:   Veterans Affairs

Multiple observational studies have consistently reported an increased risk of certain B‐cell lymphomas with hepatitis C virus (HCV) infection.[1](#hep41389-bib-0001){ref-type="ref"}, [2](#hep41389-bib-0002){ref-type="ref"}, [3](#hep41389-bib-0003){ref-type="ref"}, [4](#hep41389-bib-0004){ref-type="ref"}, [5](#hep41389-bib-0005){ref-type="ref"}, [6](#hep41389-bib-0006){ref-type="ref"}, [7](#hep41389-bib-0007){ref-type="ref"} Chronic antigen stimulation of lymphocytes is a hypothesized mechanism in HCV‐associated lymphoma,[8](#hep41389-bib-0008){ref-type="ref"} followed by a second oncogenic or proliferative "hit" that may be antigen independent.[9](#hep41389-bib-0009){ref-type="ref"}, [10](#hep41389-bib-0010){ref-type="ref"} Although not as strong and consistent as the associations with lymphoma, HCV has also been associated with many other hematologic malignancies, including myeloma, chronic lymphocytic leukemia, and myeloid leukemias,[11](#hep41389-bib-0011){ref-type="ref"}, [12](#hep41389-bib-0012){ref-type="ref"}, [13](#hep41389-bib-0013){ref-type="ref"} as well as with monoclonal gammopathy of unknown significance (MGUS),[14](#hep41389-bib-0014){ref-type="ref"}, [15](#hep41389-bib-0015){ref-type="ref"} a premalignant precursor of multiple myeloma.

Small‐case series have shown patients in whom eradication of HCV either with interferon (IFN) or direct‐acting antivirals (DAAs) led to regression or even cure of low‐grade non‐Hodgkin lymphoma.[16](#hep41389-bib-0016){ref-type="ref"}, [17](#hep41389-bib-0017){ref-type="ref"}, [18](#hep41389-bib-0018){ref-type="ref"}, [19](#hep41389-bib-0019){ref-type="ref"}, [20](#hep41389-bib-0020){ref-type="ref"}, [21](#hep41389-bib-0021){ref-type="ref"}, [22](#hep41389-bib-0022){ref-type="ref"} In addition, eradication of HCV may prevent relapse after successful treatment of high‐grade, diffuse, large B‐cell lymphoma.[23](#hep41389-bib-0023){ref-type="ref"}

Whether HCV eradication reduces the risk of developing hematologic malignancies has not been firmly established either for IFN‐based treatments or for DAAs. Hematologic malignancies are relatively rare, and a large number of treated patients would need to be followed for a long time for a sufficient number of events to accrue to enable a comparison between patients who eradicate the virus (sustained virologic response \[SVR\]) and those who do not. Furthermore, studies must be conducted separately for patients treated with IFN versus DAA treatments because IFN has putative antineoplastic and immunomodulatory effects and because IFN and DAAs have very different SVR rates and encompass different nonoverlapping eras. A recent study failed to show a statistically significant association between patients treated with IFN who achieved SVR and those who did not with respect to the risk of non‐Hodgkin lymphoma, although it approached statistical significance (adjusted hazard ratio \[AHR\], 0.71; *P* = 0.1).[24](#hep41389-bib-0024){ref-type="ref"} However, treatment and follow‐up data in that study only extended to 2009, and hematologic malignancies other than non‐Hodgkin lymphoma were not investigated. To our knowledge, the association between DAA‐induced SVR and hematologic malignancies has not been investigated. DAAs are well tolerated, lead to SVR in the majority of patients, and have led to a dramatic increase in the number of patients infected with HCV undergoing treatment. However, DAAs are extremely expensive, and concerns have been raised that the long‐term clinical benefits of DAA‐based antiviral treatment and SVR have not been adequately ascertained.[25](#hep41389-bib-0025){ref-type="ref"}

We aimed to compare patients who achieved SVR to those who failed treatment with respect to the risk of developing hematologic malignancies, independently for patients treated with IFN and those treated with DAA. We used data from the Veterans Affairs (VA) national health care system, which provides the greatest number of antiviral treatment of any health care system in the United States.

Patients and Methods {#hep41389-sec-0002}
====================

Data Source {#hep41389-sec-0003}
-----------

The VA health care system is the largest integrated health care system in the United States, currently serving more than 8.9 million veterans at 168 VA medical centers and 1,053 outpatient clinics throughout the country.[26](#hep41389-bib-0026){ref-type="ref"} The Veterans Health Administration uses a single, nationwide, comprehensive electronic health care information network (known as the Veterans Information Systems and Technology Architecture \[VistA\]) that consists of nearly 180 applications of clinical, financial, administrative, and infrastructure needs integrated into a single common database of all veterans' health information. We obtained electronic data on all patients who initiated antiviral treatment in the VA system, using the VA Corporate Data Warehouse (CDW), a national continually updated repository of data from VistA developed specifically to facilitate research.[27](#hep41389-bib-0027){ref-type="ref"} Data extracted included all patient pharmacy prescriptions, demographics, inpatient and outpatient visits, problem lists, procedures, vital signs, diagnostic tests, and laboratory tests. The study was approved by the Institutional Review Board of the VA Puget Sound Health Care System.

Study Population {#hep41389-sec-0004}
----------------

We identified all HCV antiviral regimens (n = 105,366 regimens in 78,944 patients) initiated in the VA during 17 calendar years from January 1, 1999, to December 31, 2015, with patients followed until June 30, 2018. We excluded 2,762 patients who had a diagnosis hematologic malignancy or any of the control/comparison malignancies shown in Table [1](#hep41389-tbl-0001){ref-type="table"} ever recorded prior to their first HCV antiviral treatment, 114 who died within 180 days from the start date of antiviral treatment or had fewer than 180 days of available follow‐up, and 254 patients who were diagnosed with any one of the malignancies of interest within 180 days from the start date of their antiviral treatment because these cases were very unlikely to be incident (new) cases. We excluded 6,233 patients with missing SVR data, leaving 69,581 patients in the current analysis.

###### 

Diagnostic Criteria Based on ICD‐9 and ICD‐10 Codes for Different Hematologic Malignancies, MGUS, and Two Solid Malignancies (Colon Cancer and Prostate Cancer) that Served as Negative Controls

  Disease                                     ICD‐9                                                                                                                                            ICD‐10
  ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------
  Lymphoma                                    200.x, 201.x, 202.0x, 202.1x, 202.2x, 202.7x, 202.8x, 273.3                                                                                      C81.x, C82.x, C83.x, C84.x, C85.x, C88.0, C88.4
  Multiple myeloma and plasma cell diseases   203.x, 238.6                                                                                                                                     C90.x
  Other hematologic malignancies                                                                                                                                                               
  Histiocyte/mast cell diseases               202.3x, 202.5x, 202.6x                                                                                                                           C96.0x, C96.1x, C96.2x, C96.3x
  Chronic lymphocytic leukemia                204.1x                                                                                                                                           C91.1x
  Acute lymphocytic leukemia                  204.0x                                                                                                                                           C91.0x
  Acute nonlymphocytic leukemia               205.0x, 206.0x                                                                                                                                   C92.0x, C92.4x, C92.5x, C93.0x
  Other leukemias                             202.4x, 204.2x, 204.8x, 204.9x, 205.1x, 205.2x, 205.8x, 205.9x, 206.1x, 206.2x, 206.8x, 206.9x, 207.8x, 208.0x, 208.1x, 208.2x, 208.8x, 208.9x   C91.4x, C91.Zx, C91.9x, C92.1x, C92.3x, C92.Zx, C92.9x, C93.1x, C93.9x, C93.Zx, C94.3x, C94.8x, C95.x
  Unclassified hematologic malignancy         202.9x                                                                                                                                           C96.7x, C96.9x
  MGUS                                        273.1                                                                                                                                            D47.2
                                                                                                                                                                                               
  Selected solid organ malignancies                                                                                                                                                            
  Colon cancer                                153.x                                                                                                                                            C18.x
  Prostate cancer                             185.x                                                                                                                                            C61.x
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Antiviral Treatment Regimens {#hep41389-sec-0005}
----------------------------

The regimens were divided into the following: IFN only, which included pegylated (PEG)‐IFN and regular IFN with or without ribavirin but without DAAs; DAA only, which included only IFN‐free DAA regimens (with or without ribavirin).

An additional category of DAA + IFN regimens used for a brief period from 2011 to 2013 was identified that included PEG in combination with a DAA (nonstructural protein \[NS\]3/4, NS5A, or NS5B inhibitors). This category was analyzed separately because we did not want to contaminate either the IFN‐only or the DAA‐only categories. The DAA + IFN category included only a small number of regimens and outcomes (e.g., a total of 17 incident lymphomas), precluding robust conclusions; hence, the results are reported in Supporting Table [S1](#hep41389-sup-0001){ref-type="supplementary-material"}. All VA pharmacy data are included in the CDW; dispensed drugs (rather than just prescribed drugs) were used to define antiviral treatment regimens, as we previously reported.[28](#hep41389-bib-0028){ref-type="ref"}, [29](#hep41389-bib-0029){ref-type="ref"}, [30](#hep41389-bib-0030){ref-type="ref"}, [31](#hep41389-bib-0031){ref-type="ref"}, [32](#hep41389-bib-0032){ref-type="ref"}, [33](#hep41389-bib-0033){ref-type="ref"}

Baseline Patient Characteristics {#hep41389-sec-0006}
--------------------------------

For each HCV treatment regimen, we collected baseline data, including age, sex, body mass index (BMI), HCV genotype, HCV viral load, and receipt of prior antiviral treatment. We extracted relevant laboratory tests prior to treatment and recorded the value of each test closest to the treatment starting date within the preceding 6 months. We defined hepatitis B virus (HBV) coinfection by a positive HBV surface antigen test or viral load. We also determined the presence of cirrhosis, manifestations of decompensated cirrhosis (ascites, encephalopathy, gastroesophageal varices, and hepatorenal syndrome), type 2 diabetes mellitus, alcohol use disorders, substance use disorders, human immunodeficiency virus (HIV) infection, and liver transplantation based on appropriate International Classification of Diseases (ICD)‐9 or ICD‐10 codes recorded at least twice on two separate dates before treatment initiation in any inpatient or outpatient encounter (these codes are shown in Supporting Table [S2](#hep41389-sup-0001){ref-type="supplementary-material"}). The ICD‐based definitions of these comorbidities have been widely used and validated in studies using VA medical records.[34](#hep41389-bib-0034){ref-type="ref"}, [35](#hep41389-bib-0035){ref-type="ref"}, [36](#hep41389-bib-0036){ref-type="ref"}, [37](#hep41389-bib-0037){ref-type="ref"}, [38](#hep41389-bib-0038){ref-type="ref"}, [39](#hep41389-bib-0039){ref-type="ref"}, [40](#hep41389-bib-0040){ref-type="ref"}

SVR {#hep41389-sec-0007}
---

We defined SVR as a serum HCV RNA viral load test below the lower limit of detection performed at least 12 weeks after the end of HCV treatment.[41](#hep41389-bib-0041){ref-type="ref"}

Incident Hematologic Malignancies, MGUS, Colon Cancer, and Prostate Cancer {#hep41389-sec-0008}
--------------------------------------------------------------------------

We identified incident hematologic malignancies (including lymphoma, multiple myeloma, and other hematologic malignancies) and MGUS diagnosed for the first time at least 180 days after the initiation of antiviral treatment based on appropriate ICD‐9 and ICD‐10 codes (see Table [1](#hep41389-tbl-0001){ref-type="table"}) and documented at least twice on two separate dates, some of which were validated in the VA data.[4](#hep41389-bib-0004){ref-type="ref"}, [24](#hep41389-bib-0024){ref-type="ref"} Malignancies diagnosed within 180 days from antiviral treatment initiation were excluded because eradication of HCV would be unlikely to prevent the development of a malignancy so quickly, while conversely, the presence of occult malignancy during the antiviral treatment might reduce the chances of SVR, thus creating a spurious association between SVR and lower malignancy risk.

We further extracted two additional malignancies, colon cancer and prostate cancer, as negative controls (Table [1](#hep41389-tbl-0001){ref-type="table"}). These are malignancies that are relatively common and have no plausible association with HCV or with IFN or DAAs. Therefore, any association between SVR and reduced risk in these malignancies would likely be spurious and would alert us to residual bias in our analyses.

Statistical Analysis {#hep41389-sec-0009}
--------------------

We compared patients who achieved SVR to those who did not with respect to the risk of developing the malignancies of interest, using Cox proportional hazards regression with or without adjusting for potential confounders. We calculated time starting from 180 days after initiation of antiviral treatment because cancers diagnosed within 180 days of the treatment start date could not possibly have been prevented by antiviral treatment and might have been present but undiagnosed at the time of antiviral treatment initiation (i.e., not truly incident cancers). In sensitivity analyses, we extended this period to 2 years after initiation of antiviral treatment. Follow‐up for incident malignancies extended until June 30, 2018, so that even the patients treated in late 2015 (i.e., the most recent in our cohort) would have 2.5 years of follow‐up. Patients without incident events were censored at the time of death or last follow‐up in the VA.

We considered using the date treatment ended or the date at which SVR was ascertained as the starting times for the time‐to‐event analysis; however, we decided against that because of the long and variable duration of the treatment and the interval from treatment end date to ascertainment of SVR, both of which are strongly related to SVR and would therefore introduce significant bias.

In our primary analyses, we analyzed each patient's first antiviral treatment regimen (i.e., an intention‐to‐treat analysis). A significant proportion (42.7%) of patients who did not achieve SVR after their first treatment received more than one antiviral treatment during the study period. These patients were censored at the time of initiation of a subsequent antiviral regimen that resulted in SVR, if such a regimen existed. Additionally, we performed a secondary analysis in which we analyzed all treatments that each patient received clustered by patient. The intragroup correlation induced by clustering was accounted for by using robust variance estimation. Follow‐up time was censored at the start of a regimen of a different type.

To determine if SVR was independently associated with the malignancies of interest, our multivariable proportional hazards models were adjusted for the following characteristics that may be associated with both SVR and malignancy risk, ascertained at the time of treatment initiation: cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, BMI, HCV viral load, HIV coinfection, type 2 diabetes mellitus, alcohol use disorders, substance use disorders, liver transplantation, platelet count, serum bilirubin, serum creatinine, serum albumin, serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, blood international normalized ratio (INR), and blood hemoglobin levels. Continuous variables were categorized and modeled as dummy categorical variables. In addition, we considered adjusting for the duration of IFN treatment to account for any direct antineoplastic effects of IFN itself when comparing patients who achieved SVR versus those who did not.

Results {#hep41389-sec-0010}
=======

Characteristics of the Study Population {#hep41389-sec-0011}
---------------------------------------

Of 69,581 patients, 40,410 received the IFN‐only regimen (of whom 36% achieved SVR), 4,546 received DAA + IFN (of whom 61% achieved SVR), and 24,625 received the DAA‐only regimen (of whom 90% achieved SVR). The distribution of individual regimens is shown in Supporting Table [S3](#hep41389-sup-0001){ref-type="supplementary-material"}. The most common DAA‐only regimen was sofosbuvir/ledipasvir, which accounted for 58% of all DAA‐only regimens.

Patients were mostly male individuals (96.5%), with a majority being white (56.4%) but a significant representation of other racial/ethnic groups. Mean age was 55.6 years, and 17.1% had cirrhosis, 5% decompensated cirrhosis, and 1.6% were liver transplant recipients. Genotype 1 HCV infection predominated (72%), followed by genotype 2 (12%) and 3 (8%).

Among all three regimen types, patients who achieved SVR were less likely to have diabetes, cirrhosis, or decompensated cirrhosis than patients who did not achieve SVR (Table [2](#hep41389-tbl-0002){ref-type="table"}). Among DAA‐only regimens, patients who achieved SVR were more likely to have genotype 1 infection. Conversely, among IFN‐only regimens, patients who achieved SVR were more likely to have genotypes 2 and 3 infection.

###### 

Baseline Characteristics of Patients Infected with HCV who Received Their First Antiviral Treatment from 1999 to 2015 According to Whether they Achieved SVR

  Baseline characteristics                       All Patients (N = 69,581)   IFN Only         DAA + IFN        DAA Only                                           
  ---------------------------------------------- --------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Age, years (mean \[SD\])                       55.6 \[7.7\]                52.3 \[6.2\]     52.1 \[6.8\]     57\. \[5.9\]     57.2 \[6.7\]     60.3 \[6.9\]     60.9 \[6.7\]
  BMI, kg/m^2^ (mean \[SD\])                     28.2 \[5.3\]                28.4 \[5.2\]     28.2 \[5.2\]     28.6 \[5.3\]     28.3 \[5.0\]     28.5 \[5.8\]     27.9 \[5.4\]
  Male (%)                                       96.5                        96.9             95.6             95.5             96.3             98.1             96.5
  Race/ethnicity (%)                                                                                                                                              
  White, non‐Hispanic                            56.4                        52.7             67.4             50.6             61               53.7             53.9
  Black, non‐Hispanic                            25.1                        25.5             12.3             35.7             24.6             29.8             31.5
  Hispanic, Asian, Pacific Island, AIAN, other   7.7                         8.6              7.8              7.7              5.9              9                6.7
  Declined to answer/missing                     10.8                        13.2             12.5             5.9              8.5              7.4              7.9
  Genotype (%)                                                                                                                                                    
  Genotype 1                                     71.9                        73               42.8             98.7             95               71.7             84.4
  Genotype 2                                     12.2                        9.4              25.9             0.1              0.8              12.9             9
  Genotype 3                                     7.8                         7.8              13.8             0.7              2.3              12.4             4.7
  Genotype ≥4 or missing                         8.1                         9.8              17.5             0.6              2                3                1.9
  HCV RNA viral load \>6 million IU/mL (%)       16.5                        14.8             14.7             24.1             21.1             19.9             17.9
  HIV coinfection                                3.2                         3.3              1.7              2.1              1.5              3.9              4.2
  HBV coinfection                                1                           0.6              1                1.8              1.7              0.9              1.3
  Cirrhosis (%)                                  17.1                        13.5             7.6              29               20.8             36.6             23.9
  Decompensated cirrhosis (%)                    5                           4.2              2.3              6.9              4                13.4             6.7
  Liver transplantation (%)                      1.6                         1.5              1.3              0.3              0.5              1.1              2.2
  Diabetes (%)                                   21.6                        19.5             13.6             25.4             20.4             32.1             27.7
  Alcohol use disorder (%)                       38.7                        34.9             33.8             42.4             40.7             50.1             44.4
  Substance use disorder (%)                     31.1                        27               26.1             34.6             32.6             40.7             37.7
  Laboratory results(mean \[SD\])                                                                                                                                 
  Hemoglobin, g/dL                               14.9 \[1.5\]                15.0 \[1.5\]     15.1 \[1.4\]     14.9 \[1.4\]     15.0 \[1.4\]     14.3 \[1.7\]     14.5 \[1.6\]
  Platelet count, k/µL                           191.7 \[71.9\]              196.5 \[72.7\]   210.1 \[69.2\]   173.1 \[64.0\]   187.8 \[63.1\]   159.2 \[74.5\]   180.2 \[70.4\]
  Creatinine, mg/dL                              1.0 \[0.6\]                 1.0 \[0.7\]      1.0 \[0.4\]      1.0 \[0.7\]      0.9 \[0.3\]      1.0 \[0.5\]      1.0 \[0.5\]
  Bilirubin, g/dL                                0.7 \[0.5\]                 0.7 \[0.5\]      0.6 \[0.5\]      0.7 \[0.5\]      0.6 \[0.4\]      0.8 \[0.7\]      0.7 \[0.5\]
  Albumin g/dL                                   4.0 \[0.5\]                 4.0 \[0.5\]      4.1 \[0.4\]      3.9 \[0.5\]      4.0 \[0.4\]      3.7 \[0.6\]      3.9 \[0.5\]
  INR                                            1.1 \[1.0\]                 1.1 \[0.9\]      1.1 \[1.0\]      1.2 \[1.3\]      1.2 \[1.1\]      1.2 \[1.0\]      1.2 \[0.9\]
  AST/ALT                                        0.9 \[0.4\]                 0.9 \[0.4\]      0.8 \[0.3\]      1.0 \[0.4\]      0.8 \[0.3\]      1.0 \[0.4\]      1.0 \[0.4\]

Abbreviation: AIAN, American Indian and Alaskan Native.
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Compared to patients treated in the IFN‐only category, those treated only with DAA had a higher mean age (by 8 years) and were more likely to have cirrhosis, alcohol use disorders, and substance use disorders.

IFN‐Induced SVR was Associated with Reduction in Hematologic Malignancies {#hep41389-sec-0012}
-------------------------------------------------------------------------

Of the 40,410 patients treated only with IFN with mean follow‐up of 10.6 years from treatment initiation, 348 developed lymphoma, 121 multiple myeloma, 159 other hematologic malignancies, 225 MGUS, 260 colon cancer, and 1,361 prostate cancer. Among patients treated with IFN, SVR was significantly associated with a reduction in the risk of lymphoma (AHR, 0.70; 95% confidence interval \[CI\], 0.51‐0.97), multiple myeloma (AHR, 0.40; 95% CI, 0.20‐0.77), MGUS (AHR, 0.65; 95% CI, 0.42‐0.99), or all hematologic malignancies and MGUS combined (AHR, 0.67; 95% CI, 0.53‐0.84) in both crude and adjusted analyses (Table [3](#hep41389-tbl-0003){ref-type="table"}; Fig. [1](#hep41389-fig-0001){ref-type="fig"}). Among patients treated with IFN, SVR was not associated with colon cancer (AHR, 1.13; 95% CI, 0.81‐1.58) or prostate cancer (AHR, 1.14; 95% CI, 0.98‐1.33), the two negative control malignancies that we studied.

###### 

Association Between Eradication of HCV (SVR) and Risk of Lymphoma, Multiple Myeloma, Other Hematologic Malignancies, MGUS, Colon Cancer, and Prostate Cancer, Presented Separately According to Treatment with IFN‐only Versus DAA‐only Regimens

                                                                                 Number of Patients   Patient Years   Number Who Developed Malignancy (%)   Incidence per 100 Patient Years   Crude HR (95% CI)   AHR[\*](#hep41389-note-0005){ref-type="fn"} (95% CI)
  -------------------------------------------------------------- --------------- -------------------- --------------- ------------------------------------- --------------------------------- ------------------- ------------------------------------------------------
  Lymphoma                                                                                                                                                                                                        
  IFN‐only regimens                                              No SVR          26,078 (64.5)        263,705         256 (1.0)                             0.1                               1                   1
  SVR                                                            14,332 (35.5)   144,887              92 (0.6)        0.06                                  0.66 (0.52‐0.83)                  0.70 (0.51‐0.97)    
  DAA‐only regimens                                              No SVR          2,524 (10.2)         6,140           12 (0.5)                              0.2                               1                   1
  SVR                                                            22,101 (89.8)   53,706               82 (0.4)        0.15                                  0.78 (0.43‐1.43)                  0.91 (0.47‐1.76)    
  Multiple myeloma                                                                                                                                                                                                
  IFN‐only regimens                                              No SVR          26,078 (64.5)        264,195         100 (0.4)                             0.04                              1                   1
  SVR                                                            14,332 (35.5)   145,178              21 (0.1)        0.01                                  0.38 (0.24‐0.61)                  0.40 (0.20‐0.77)    
  DAA‐only regimens                                              No SVR          2,524 (10.2)         6,155           1 (0.0)                               0.02                              1                   1
  SVR                                                            22,101 (89.8)   53,772               19 (0.1)        0.04                                  2.17 (0.29‐16.18)                 1.85 (0.23‐14.71)   
  Other hematologic malignancies (except lymphoma and myeloma)                                                                                                                                                    
  IFN‐only regimens                                              No SVR          26,078 (64.5)        264,104         123 (0.5)                             0.05                              1                   1
  SVR                                                            14,332 (35.5)   145,111              36 (0.3)        0.02                                  0.53 (0.37‐0.77)                  0.65 (0.38‐1.12)    
  DAA‐only regimens                                              No SVR          2,524 (10.2)         6,153           3 (0.1)                               0.05                              1                   1
  SVR                                                            22,101 (89.8)   53,786               21 (0.1)        0.04                                  0.80 (0.24‐2.68)                  0.90 (0.25‐3.16)    
  MGUS                                                                                                                                                                                                            
  IFN‐only regimens                                              No SVR          26,078 (64.5)        263,891         174 (0.7)                             0.07                              1                   1
  SVR                                                            14,332 (35.5)   145,020              51 (0.4)        0.04                                  0.54 (0.39‐0.74)                  0.65 (0.42‐0.99)    
  DAA‐only regimens                                              No SVR          2,524 (10.2)         6,151           5 (0.2)                               0.08                              1                   1
  SVR                                                            22,101 (89.8)   53,689               71 (0.3)        0.13                                  1.60 (0.64‐3.96)                  1.54 (0.56‐4.27)    
  Hematologic malignancies or MGUS                                                                                                                                                                                
  IFN‐only regimens                                              No SVR          26,078 (64.5)        262,325         574 (2.2)                             0.22                              1                   1
                                                                 SVR             14,332 (35.5)        144,534         183 (1.3)                             0.13                              0.58 (0.49‐0.69)    0.67 (0.53‐0.84)
  DAA‐only regimens                                              No SVR          2,524 (10.2)         6,133           20 (0.8)                              0.33                              1                   1
  SVR                                                            22,101 (89.8)   53,561               179 (0.8)       0.33                                  1.02 (0.64‐1.62)                  1.08 (0.66‐1.78)    
  Colon cancer                                                                                                                                                                                                    
  IFN‐only regimens                                              No SVR          26,078 (64.5)        263,834         165 (0.6)                             0.06                              1                   1
  SVR                                                            14,332 (35.5)   144,846              95 (0.7)        0.07                                  1.05 (0.81‐1.35)                  1.13 (0.81‐1.58)    
  DAA‐only regimens                                              No SVR          2,524 (10.2)         6,153           2 (0.1)                               0.03                              1                   1
  SVR                                                            22,101 (89.8)   53,757               41 (0.2)        0.08                                  2.31 (0.56‐9.53)                  4.60 (0.62‐33.93)   
  Prostate cancer                                                                                                                                                                                                 
  IFN‐only regimens                                              No SVR          26,078 (64.5)        259,757         902 (3.5)                             0.35                              1                   1
  SVR                                                            14,332 (35.5)   142,813              459 (3.2)       0.32                                  0.93 (0.83‐1.04)                  1.14 (0.98‐1.33)    
  DAA‐only regimens                                              No SVR          2,524 (10.2)         6,121           28 (1.1)                              0.46                              1                   1
  SVR                                                            22,101 (89.8)   53,428               288 (1.3)       0.54                                  1.18 (0.80‐1.74)                  1.03 (0.68‐1.56)    
  Colon cancer or prostate cancer                                                                                                                                                                                 
  IFN‐only regimens                                              No SVR          26,078 (64.5)        259,017         1,059 (4.1)                           0.41                              1                   1
  SVR                                                            14,332 (35.5)   142,440              548 (3.8)       0.38                                  0.94 (0.85‐1.05)                  1.14 (0.99‐1.31)    
  DAA‐only regimens                                              No SVR          2,524 (10.2)         6,119           30 (1.2)                              0.49                              1                   1
  SVR                                                            22,101 (89.8)   53,381               329 (1.5)       0.62                                  1.25 (0.86‐1.82)                  1.18 (0.79‐1.77)    

Adjusted for cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, BMI, HCV genotype, length of treatment, HCV viral load, HIV coinfection, type 2 diabetes mellitus, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin, serum AST/ALT ratio, blood INR, and blood hemoglobin levels. Laboratory tests were categorized into quartiles and modeled as dummy categorical variables.
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![Cumulative incidence curves comparing patients who achieved SVR versus those who did not after treatment with IFN (panels A and B) or DAAs (panels C and D). Patients with IFN‐induced SVR have lower cumulative incidence of hematologic malignancies or MGUS compared to patients who did not achieve SVR (A). Furthermore, the difference between the "SVR" and "No SVR" cumulative incidence curves in panel A continues to expand as more time accrues after treatment up to 10 years. In contrast, patients with DAA‐induced SVR have almost identical cumulative incidence of hematologic malignancies as the patients who did not achieve SVR (C). Although follow‐up only extends for 3 years from the time point 6 months after DAA treatment initiation, the equivalent curves appear to separate by 3 years after IFN treatment in panel A. As expected, there is no difference between patients with and without SVR following either IFN or DAA in the cumulative incidence of the "negative control" malignancies of colon and prostate cancer -- which have no putative relationship with HCV or IFN (B and D). \[Corrections added 13 June 2019. In the original publication the captions for Figure 1 panels A through D were omitted.\]](HEP4-3-1124-g001){#hep41389-fig-0001}

DAA‐Induced SVR was not Associated with Reduction in Hematologic Malignancies {#hep41389-sec-0013}
-----------------------------------------------------------------------------

Of the 24,625 patients treated only with DAA with mean follow‐up of 2.9 years from treatment initiation, 94 developed lymphoma, 20 multiple myeloma, 24 other hematologic malignancies, 76 MGUS, 43 colon cancer, and 316 prostate cancer. Among patients treated with DAA, SVR was not associated in unadjusted or adjusted models with a reduction in any of these malignancies individually or when all hematologic malignancies or all solid malignancies were combined (Table [3](#hep41389-tbl-0003){ref-type="table"}; Fig. [1](#hep41389-fig-0001){ref-type="fig"}).

Additional Analyses and Considerations Attempting to Explain the Discrepancy Between IFN‐Induced SVR And DAA‐Induced SVR {#hep41389-sec-0014}
------------------------------------------------------------------------------------------------------------------------

A test of statistical interaction for risk of hematologic malignancy or MGUS versus HCV treatment and SVR, after adjusting for other predictors, was performed (*P* = 0.05) and supported the role of effect modification by regimen type rather than differences in sample size. To evaluate the possibility of effect modification by age in which SVR could exert a protective effect against hematologic malignancies only among young patients (and thus result in a greater impact in the younger IFN‐treated cohort), stratification by age groups was performed (Supporting Table [S4](#hep41389-sup-0001){ref-type="supplementary-material"}). Even when limiting our analyses to patients \<65 or \<60 years old, there was no association between DAA‐induced SVR and hematologic malignancies, while the association between IFN‐induced SVR and reduced risk of hematologic malignancies persisted unchanged.

We selected 20 confounding variables *a priori* as those potentially associated with both SVR and hematological malignancy. To ensure that simultaneously adjusting for a large number of variables did not result in overfitting, we conducted secondary analyses that modeled different levels of adjustment. These included unadjusted; adjusted for the most important predictors of SVR, including cirrhosis, decompensated cirrhosis, HCV genotype, and diabetes; adjusted for the most important predictors of SVR and critical demographics comprising cirrhosis, decompensated cirrhosis, HCV genotype, diabetes, age, sex, race/ethnicity, and BMI; and adjusted for all 20 potential confounders selected *a priori*. AHRs were consistent across the different levels of adjustment (Supporting Table [S5](#hep41389-sup-0001){ref-type="supplementary-material"}).

We performed additional analyses in which we excluded the first 2 years of follow‐up after treatment instead of only 180 days. IFN regimens were associated with multiple side effects, including cytopenias, which frequently led to early discontinuation and failure to achieve SVR.[35](#hep41389-bib-0035){ref-type="ref"} It is possible that hematologic malignancies might have been present but occult during the antiviral treatment or present in premalignant forms, exacerbating treatment‐related cytopenias and leading to early discontinuation and/or treatment failure. We reasoned that such hematologic malignancies that were present but occult at the time of treatment would be diagnosed within 2 years. However, the association between IFN‐induced SVR and reduced risk of lymphoma, multiple myeloma, or MGUS was even stronger after excluding the first 2 years, thus ruling out this potential source of bias (Supporting Table [S6](#hep41389-sup-0001){ref-type="supplementary-material"}). Furthermore, the cumulative incidence curves of the patients treated with IFN who achieved SVR and those who did not continued to separate from each other even up to 10 years of follow‐up (Fig. [1](#hep41389-fig-0001){ref-type="fig"}). It is extremely unlikely that this would be caused by occult malignant or premalignant conditions present so many years before the antiviral treatment.

IFN has been used as treatment of some hematologic malignancies (e.g., multiple myeloma, lymphoma, chronic myeloid leukemia). It is therefore conceivable that the IFN that was given to treat HCV might have also treated an occult or developing hematologic malignancy. However, both patients with and without SVR received IFN, and any such effect would have canceled out. We additionally adjusted for duration of IFN treatment in the event that patients who achieved SVR received longer IFN treatment and hence more antineoplastic benefits, but the associations with IFN‐related SVR persisted.

Among patients treated with IFN, those who achieved SVR had identical mean follow‐up duration (10.6 years) as those who did not (10.6 years) and were treated during the same calendar years. Therefore, unequal follow‐up time or changes over time in the ascertainment of malignancies cannot explain the associations between IFN‐induced SVR and lower risk of hematologic malignancies.

Patients treated only with DAA had much shorter mean follow‐up duration (2.9 years) than patients treated with IFN. It is possible that follow‐up in the patients treated with DAA was not long enough for the effects of DAA‐induced SVR on hematologic malignancy to manifest. While this may be true, it appears that among the patients treated with IFN, the cumulative incidence curves of the patients who achieved SVR and those who did not separate from each other even within the first 3 years (Fig. [1](#hep41389-fig-0001){ref-type="fig"}), whereas the curves for the patients treated with DAA do not. We performed a secondary analysis in which follow‐up of patients treated with IFN and those treated with DAA was truncated at 3 years (Supporting Table [S7](#hep41389-sup-0001){ref-type="supplementary-material"}). An association of reduced risk of hematologic malignancies or MGUS in IFN‐induced SVR was observed in the unadjusted model; in the adjusted model, the association did not meet statistical significance, likely due to fewer incident hematologic malignancies in this period of time.

Our primary analysis included only the first antiviral treatment that patients received. However, many patients received multiple treatment courses, especially many patients treated with DAA who had previously failed treatments with IFN. For this reason, we performed additional analyses that included all treatment courses received (n = 85,200) among the 69,581 patients in our study, using cluster analysis (Supporting Table [S8](#hep41389-sup-0001){ref-type="supplementary-material"}). The associations with IFN‐induced SVR persisted and if anything were slightly stronger, whereas again no associations were identified with DAA‐induced SVR.

Discussion {#hep41389-sec-0015}
==========

We report for the first time that IFN‐induced SVR is associated with a significant reduction in the risk of hematologic malignancies (including lymphoma and multiple myeloma) and MGUS during a mean follow‐up of 10.6 years from treatment. In contrast, DAA‐induced SVR was not associated with a reduction in the risk of hematologic malignancies, albeit during a shorter mean follow‐up of 2.9 years from treatment. This suggests that the eradication of HCV may have different long‐term benefits depending on whether it is achieved by IFN or DAAs.

Multiple observational studies have consistently reported an increased risk of certain B‐cell lymphomas with HCV infection.[1](#hep41389-bib-0001){ref-type="ref"}, [2](#hep41389-bib-0002){ref-type="ref"}, [3](#hep41389-bib-0003){ref-type="ref"}, [4](#hep41389-bib-0004){ref-type="ref"}, [5](#hep41389-bib-0005){ref-type="ref"} HCV has also been associated with the development of MGUS[14](#hep41389-bib-0014){ref-type="ref"}, [15](#hep41389-bib-0015){ref-type="ref"} and many other hematologic malignancies, including myeloma, T‐cell lymphomas, chronic lymphocytic leukemia, and myeloid leukemias, but these associations have not been confirmed across studies.[11](#hep41389-bib-0011){ref-type="ref"}, [12](#hep41389-bib-0012){ref-type="ref"}, [13](#hep41389-bib-0013){ref-type="ref"} Neither the pathogenic mechanism of HCV contributing risk to hematologic malignancies nor the effect on this risk of SVR is well characterized.[42](#hep41389-bib-0042){ref-type="ref"} Chronic antigen stimulation of lymphocytes is a hypothesized mechanism in HCV‐associated lymphoma.[8](#hep41389-bib-0008){ref-type="ref"} Alternatively or in combination, a direct oncogenic effect by HCV may occur through infection of B cells by virus or engagement by HCV‐E2 protein of B‐cell and T‐cell surface receptor clusters of differentiation (CD)81.[43](#hep41389-bib-0043){ref-type="ref"} Furthermore, eradication of HCV either with IFN or DAAs has led to regression or prevention of relapse in certain cases of lymphoma.[16](#hep41389-bib-0016){ref-type="ref"}, [17](#hep41389-bib-0017){ref-type="ref"}, [18](#hep41389-bib-0018){ref-type="ref"}, [19](#hep41389-bib-0019){ref-type="ref"}, [20](#hep41389-bib-0020){ref-type="ref"}, [21](#hep41389-bib-0021){ref-type="ref"}, [22](#hep41389-bib-0022){ref-type="ref"}, [23](#hep41389-bib-0023){ref-type="ref"}

Even assuming that HCV is causatively associated with hematologic malignancies, it does not necessarily follow that eradication of HCV should reduce the risk. Most patients have been infected for decades before undergoing treatment and eradication. It is plausible that groundwork for tumorigenesis was already laid during the long period of infection and the occurrence of future mutagenic hits that complete a cell's neoplastic conversion are unrelated to HCV and may occur even after HCV eradication. A Japanese study extending from 1969 to 2006 reported that none of the 1,048 patients who achieved SVR with IFN developed lymphoma compared to 12 cases of lymphoma among 1,660 patients treated with IFN who failed to achieve SVR.[44](#hep41389-bib-0044){ref-type="ref"} These results suggest that SVR induced by IFN may be protective for the development of HCV‐related lymphoma; however, no multivariable adjustments for baseline characteristics that could be confounders were performed, and the likelihood of diagnosis of lymphoma might have changed during the almost 40‐year study period. Recently, Mahale et al.[24](#hep41389-bib-0024){ref-type="ref"} reported that patients with IFN‐induced SVR had significantly lower risk of non‐Hodgkin lymphoma compared with patients who were untreated (AHR, 0.64; 95% CI, 0.43‐0.95) but not compared with patients who received IFN and did not achieve SVR (AHR, 0.71; 95% CI, 0.45‐1.11). Like ours, this study was also based on national VA data but only extended from 1999 to 2009; our study extended from 1999 to 2018, which may explain why that study did not reach statistical significance even though the AHR for lymphoma was remarkably similar to the one we reported (AHR, 0.70; 95% CI, 0.51‐0.97). In addition to showing a significant association with lymphoma, our results demonstrated a significant association between IFN‐induced SVR and a reduction in multiple myeloma (AHR, 0.40; 95% CI, 0.20‐0.77) and MGUS (AHR, 0.65; 95% CI, 0.42‐0.99) as well as all hematologic malignancies and MGUS combined (AHR, 0.67; 95% CI, 0.53‐0.84). In fact, the magnitude of the association between IFN‐induced SVR and reduced multiple myeloma or MGUS was greater than that for lymphoma. We are not aware of prior studies that investigated the effect of HCV antiviral treatments on hematologic malignancies other than lymphoma.

In contrast, we found no association between DAA‐induced SVR and lymphoma, myeloma, MGUS, or all hematologic malignancies and MGUS combined. Mean follow‐up (2.9 years from treatment) was unavoidably shorter in the patients treated with DAA than in the patients treated with IFN, but it was as long as could possibly be at the time the analysis was done because we extended follow‐up to June 30, 2018, and began with the earliest DAA‐only regimens available. We are not aware that this association has been tested in other large community‐based databases of DAA treatments, and it merits confirmation. Also, it would be important to repeat this analysis in 2‐3 years when more follow‐up time has accrued. This finding is surprising because we are not aware of other long‐term outcomes where IFN‐induced SVR has been convincingly shown to have different implications than DAA‐induced SVR. For example, we have previously shown that DAA‐induced SVR and IFN‐induced SVR have similar effects on reducing the risk of hepatocellular carcinoma.[45](#hep41389-bib-0045){ref-type="ref"}

Critical to understanding the relationship between IFN‐induced SVR and reduced incidence of hematologic malignancies is the direct role of IFN in either treating early stage or subclinical malignancy or enhancing immune surveillance as a prophylactic intervention. IFN is well established as a promoter of immune response to malignancy as evidenced, for example, by the increased rate of cancer in mice lacking the IFN signaling gene interferon alpha and beta receptor subunit 1 (*Ifnar1*).[46](#hep41389-bib-0046){ref-type="ref"} IFN has a long history of use treating various hematologic malignancies, albeit with limited success, including chronic myeloid leukemia, myeloma, and lymphoma.[47](#hep41389-bib-0047){ref-type="ref"}, [48](#hep41389-bib-0048){ref-type="ref"}, [49](#hep41389-bib-0049){ref-type="ref"}, [50](#hep41389-bib-0050){ref-type="ref"} Therefore, it is plausible that IFN‐induced SVR has a particularly strong effect on hematologic malignancies through the positive interaction of both the pharmacologic effects of IFN itself and the effects of viral eradication. Such an interaction needs to be invoked because patients with SVR and those without SVR were exposed to IFN, and hence the pharmacologic effects of IFN alone cannot explain our finding. Although we went to great lengths to exclude a spurious or biased finding, as explained in the Results section (e.g., including negative control malignancies, excluding 6 months and 2 years of follow‐up, adjusting for duration of IFN treatment as well as 20 other potential confounders, ensuring a sufficiently long follow‐up time, performing cluster analyses as well as first‐treatment analyses), we cannot completely exclude the possibility that patients who failed IFN treatments also happened to have characteristics that we did not adjust for that predisposed them to hematologic malignancies many years later.

The use of VA data enabled this large study; however, the cohort is heavily skewed to men. It would be important for other large community‐based cohorts of patients treated for HCV to confirm our findings. The accuracy of the data herein is contingent on coding of malignancies by health care providers in the VA electronic health records system. Efforts to optimize this included the stringent definition of a diagnosis of malignancy or MGUS by recording ICD‐9 or ICD‐10 codes 2 or more times on two different dates. Validated, previously published, diagnostic coding libraries were used when available, including specifically from VA‐based studies. Certain ICD codes, such as ICD‐9 202.8x, designate B‐cell non‐Hodgkin lymphoma but can be used for multiple histologic subtypes. This can result in the dilution of rare lymphoma subtypes more commonly associated with HCV. Although some diagnostic inaccuracies and imprecision are inevitable, there is no reason to suspect that they would be in a particular direction and more likely to occur in the SVR versus the no SVR group. Similarly, while the IFN‐treated cohort and the DAA‐treated cohort differed by era (and, potentially, changes in cancer screening practices) and factors associated with cancer incidence, including age and prevalence of cirrhosis, the comparison of SVR and no SVR groups by treatment modality are contemporaneous and not subject to these differences. Strengths of the study include large sample size, long duration of follow‐up, adequate number of incidence malignancies, appropriate comparison/control groups, and adequate adjustment for almost all factors known to be associated with SVR. Although there may be additional factors associated with hematologic malignancies and HCV, a characteristic can be a confounder only if it is associated with both SVR and the future development of hematologic malignancies. For example, mixed and polyclonal cryoglobulinemia are important extrahepatic complications of HCV and may represent a manifestation of certain hematologic malignancies. Cryoglobulinemia is not routinely documented by laboratory and diagnostic evaluations, however, and it was omitted in the analyses as there is no reason to suspect an association with SVR.

We demonstrate that IFN‐induced SVR is associated with dramatic reductions in the risk of hematologic malignancies, including lymphoma and multiple myeloma, and the premalignant condition of MGUS. In contrast, DAA‐induced SVR was not associated with such risk reductions, at least within the study's mean follow‐up of 2.9 years. We hope that studies from other large population‐based cohorts will replicate our findings and that our study will be repeated with the accrual of longer follow‐up since the introduction of DAAs. Our study cautions that we should not automatically assume that any benefits of viral eradication derived from IFN‐based treatments apply to DAA‐based treatments. It is critical to continue to evaluate the long‐term clinical benefits that patients derive from DAA treatments.
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